A practical reference on PT-141: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-09 and is reviewed periodically as new material appears.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Beginning in the 1990s, the food sector in developing countries has rapidly transformed, particularly in Latin America, South-East Asia, India, China and South Africa. With growth has come considerable competition and some amount of consolidation. The growth has been driven by: increasing affluence and the rise of a middle class; the entry of women into the workforce; a consequent incentive to seek out easy-to-prepare foods; the growth in the use of refrigerators, making it possible to shop weekly instead of daily; and the growth in car ownership, facilitating journeys to distant stores and purchases of large quantities of goods. The opportunities presented by this potential have encouraged several European companies to invest in these markets (mainly in Asia) and American companies to invest in Latin America and China. Local companies also entered the market. Initial development of supermarkets has now been followed by hypermarket growth. In addition there were investments by companies such as Makro and Metro Cash and Carry in large-scale Cash-and-Carry operations. While the growth in sales of processed foods in these countries has been much more rapid than the growth in fresh food sales, the imperative nature of supermarkets to achieve economies of scale in purchasing means that the expansion of supermarkets in these countries has important repercussions for small farmers, particularly those growing perishable crops.
=== January === The late 2000s recession has entered its second full year of existence. While many nations have managed to climb out of the recession, employment is still sparse and promises to remain so throughout 2010.
=== Endothelial colony forming cell === Endothelial colony forming cells are a late outgrowth cell type; that is, they are only isolated after significantly longer culture than CFU-Hill cells. ECFCs are isolated by plating peripheral blood mononuclear fraction on collagen-coated plates, removing non-adherent cells, and culturing for weeks until the emergence of colonies with a distinctive cobblestone morphology. These cells are phenotypically similar to endothelial cells and have been shown to create vessel-like structures in vitro and in vivo. In 2019, David Smadja described a standardized protocol for the isolation and culture of endothelial colony-forming cells (ECFCs) in humans. This was followed in 2023 by a publication surveying laboratory practices among teams working with these cells, conducted under the auspices of the International Society on Thrombosis and Haemostasis Vascular Biology Scientific Subcommittee. In 2025, a review emphasized the unique vasculogenic and immunomodulatory properties of cord blood-derived ECFCs (CB-ECFCs), highlighting their high proliferative capacity, immune-privileged status, and therapeutic potential in vascular regeneration and tissue engineering.
=== Usage of temporary foreign workers === Following the COVID-19 pandemic, Tim Hortons utilized the temporary foreign worker program (TFW) to fill employee vacancies. In December 2025, CBC News reported that the company had lobbied federal politicians to expand the program. In May 2026, Tim Hortons announced that it would seek to "hire local" and reduce its usage of the program, stating that 4,000 of its employees were hired through the TFW program as of 2026.
During the 2025–2026 Iranian protests, Trump repeatedly warned the Iranian authorities that the U.S. would "intervene" if the regime did not halt its crackdown on protesters. On January 16, 2026, Trump announced that the Iranian leadership had reportedly canceled over 800 planned executions. On February 28, 2026, Trump launched a major attack on Iran with Israel with the stated goal of regime change. On March 21, 2026, Trump announced a 48-hour ultimatum on Truth Social calling for Iran to open the Strait of Hormuz, threatening the destruction of Iranian power infrastructure. Over the following week, specifically on March 23 and 26, Trump announced two different extensions to the ultimatum. On March 26, an official pause on "the period of Energy Plant destruction" until April 2, 2026, was announced on social media, an extension he later stated was a result of Iran allowing oil-carrying ships to safely pass through the Strait of Hormuz. On April 4 and 5, 2026, Trump resumed posting threats of US attack on Iranian infrastructure, stating April 7, 2026, as the deadline for the Strait of Hormuz to be opened. On April 7, Trump posted to Truth Social that "a whole civilization will die tonight, never to be brought back again", causing domestic concern that Trump would use nuclear weapons, and resulting in a number of bipartisan calls for the 25th Amendment to be invoked. The White House confirmed in an official statement that there is currently no consideration of usage of nuclear weaponry.
Sources: en.wikipedia.org
Scientists found leprosy-causing bacteria viably regenerate and rejuvenate the liver in its armadillos hosts, which may enable novel human therapies based on knowledge or components gained from naturally evolved organisms or capabilities.
Light and temperature impact the speed of deterioration, especially in combination with other agents of decay. Exposure of any length to light causes fading. Light both visible and UV can bleach and dry textiles as well as fade color. It is recommended that light is kept at 50 lux for textiles while on display. The length of exposure to light is determined by the type of textile and the object's current condition. Physical agents of decay include the natural breakdown of biological material, which causes fabrics to become more brittle as they age. Humidity is a factor that impacts textile fibers. Loss of moisture decreases the elasticity and increases brittleness. An environment that is too humid encourages pest activity and the growth of mold. Pests affect the physical makeup of textiles by eating fibers, and this destabilizes the fabrics. Pest activity can also discolor materials. Mold weakens and stains textiles. Chemical deterioration of textiles is caused by a variety of interactions. For example, the interaction of fibres with metals, pollutants, adhesives and other even other fibers can cause deterioration. Oxidation of metal threads or adornments can discolor and tarnish textiles due to the chemical reaction between the oxygen in the air and the fibers. Pollution impacts textiles. Pollution can come from the environment or the actual textile manufacturing process. These pollutants include pollen, mold, skin cells, ash, dirt and metal dust. Sources can include the museum exhibit and storage materials and air coming in from outside the museum.
5 December Junior doctors in England will stage further strike action after rejecting the latest pay offer, the British Medical Association confirms, with a three-day strike scheduled to begin on 20 December and a six-day strike scheduled to begin on 3 January 2024. The Scottish Prison Service issues new guidelines on transgender prisoners. Trans women who have hurt or threatened women or girls will not be sent to a female prison unless there are "exceptional" circumstances. Jesse Darling is announced as the winner of the 2023 Turner Prize. 6 December Boris Johnson, who served as prime minister from 2019 to 2022, appears before the COVID-19 inquiry and is questioned by Hugo Keith, counsel to the inquiry. He apologises for the "pain and the loss and the suffering" people experienced during the pandemic. His comments are interrupted by protesters, who are ordered to leave the inquiry room. Robert Jenrick resigns as immigration minister after the government publishes an emergency Rwanda bill. 7 December Figures released by Halifax Bank indicate house prices in the UK rose by 0.5% in November 2023. Culture Secretary Lucy Frazer confirms the TV licence fee will increase by £10.50 from £159 to £169.50 from 1 April 2024. Serial killer Steve Wright is arrested for the September 1999 murder of Victoria Hall. 8 December A letter to MPs from Sir Matthew Rycroft, the Permanent Under-Secretary of State of the Home Office, says that £240m has been paid so far to Rwanda for the Rwanda asylum plan, with a further £50m to be paid in 2024.
Human iron homeostasis is regulated at two different levels. Systemic iron levels are balanced by the controlled absorption of dietary iron by enterocytes, the cells that line the interior of the intestines, and the uncontrolled loss of iron from epithelial sloughing, sweat, injuries and blood loss. In addition, systemic iron is continuously recycled. Cellular iron levels are controlled differently by different cell types due to the expression of particular iron regulatory and transport proteins.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.